Hema Tallman: Imagine Needing A Treatment So Rare, So Specific, That Only Plasma-derived Medicine Can Help
Hema Tallman, SVP- Global Head of BioLife Plasma Services at Takeda, reposted from Takeda on LinkedIn:
”Imagine needing a treatment so rare, so specific, that only plasma-derived medicine can help.
For hundreds of thousands of people around the world, this is their reality – and their hope.
At BioLife Plasma Services, our employees are the heartbeat of this hope.
We welcome donors with care, ensure safety at every step, and help transform each donation into life-sustaining medicine.
I’m inspired by the work of Thomas – and all our employees – every day.”
Takeda shared on LinkedIn:
”Plasma is required to produce life-sustaining medicine for people with rare and serious health conditions and can’t be manufactured. It’s a precious gift that comes from generous donors. But how does this life-sustaining resource get from donor to patient?
It takes dedication, care and a whole lot of heart. Our colleagues at BioLife Plasma Services are the vital starting point in this journey – ensuring a safe and welcoming experience for every donor, and collecting the plasma that transforms lives.
This International Plasma Awareness Week (IPAW), get an inside look at the inspiring work to help maintain a reliable supply of plasma for patients.”
Read more here.
Stay updated with Hemostasis Today.
-
Oct 9, 2025, 06:44Gretchen Simmons: Anyone Can Have a Blood Clot - No One Knows This Better Than Carol West
-
Oct 8, 2025, 03:07Stroke Education By Rodrigo Guerrero - On Unilateral, Nonprogressive Stenosis
-
Oct 7, 2025, 15:015 Simple Exercises By Christina P. That Support Health in Antiphospholipid Syndrome
-
Oct 7, 2025, 14:39Dr Amid Karad: Help Raise Awareness on Evidence-Based INR Management for Diverse Indications
-
Oct 7, 2025, 14:27NBCA Insights with Erin VanDyke: Revealing Gaps in Blood Clot Diagnosis and Support
-
Oct 9, 2025, 07:14Ami Bhatt: The link Between Inflammation and Atherosclerotic Cardiovascular Disease Is No Longer Theoretical
-
Oct 9, 2025, 06:59Courtney Lawrence: It's Critical That as Blood Donor Eligibility Criteria Evolves
-
Oct 9, 2025, 06:55All You Need to Know About Generative AI in Medicine from Daniel Ting and Colleagues
-
Oct 9, 2025, 06:52Cihan Ay and Colleagues on Large Language Models VS Thrombosis Experts
-
Oct 9, 2025, 06:48A Neopoterian Theory of Global Bioethics from Henri-Corto Stoeklé and Christian Hervé
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 9, 2025, 07:15Hema Tallman: Imagine Needing A Treatment So Rare, So Specific, That Only Plasma-derived Medicine Can Help
-
Oct 9, 2025, 07:07Rahaf Ajaj: It’s About How Deeply Your Idea Can Reshape The World
-
Oct 8, 2025, 04:45Reza Shojaei: On The 2nd Day of IPAW 2025, Let's Focus on Patients, The Real Reason Plasma Matters!
-
Oct 7, 2025, 08:29“48 Poems on 48 Blood Group Systems” - Dr Bhavyaa Beriwal Blends Science and Poetry in Her New Transfusion Medicine Book
-
Oct 7, 2025, 04:35Hema Tallman: During IPAW, We Honor The Unseen Heroes – Plasma Donors